Medifast, Inc. filings document the public-company disclosures of a NYSE-listed metabolic health and wellness business centered on its coach-guided lifestyle system. Form 8-K reports furnish quarterly and annual earnings releases that detail revenue, gross profit, active earning coach trends, liquidity, debt status and management commentary on the company's metabolic health strategy.
Proxy and current reports cover board elections, stockholder voting results, executive compensation, equity incentive plan amendments, leadership changes and material definitive agreements. Recent governance disclosures include a stockholder cooperation agreement, annual meeting matters and compensatory arrangements connected to executive transitions.
MEDIFAST INC director Kiai Parsa reported equity-based compensation awards rather than open-market trades. On May 26, 2026, he received 7,637 restricted stock units and a separate grant of 11,680 shares of common stock at no cash cost, in connection with his annual director fees.
According to the company’s Director's Deferred Compensation Plan, each unit represents one share of common stock, granted from the Amended and Restated 2012 Share Incentive Plan, and these shares will vest in full on May 26, 2027. The filing shows direct holdings associated with these awards of 19,317 and 11,680 shares, respectively, underscoring that this is a compensation-related acquisition, not a market purchase or sale.
Thomas Andrea B reported acquisition or exercise transactions in this Form 4 filing.
MEDIFAST INC director Andrea B. Thomas received an equity grant of 11,680 restricted stock units as part of annual director fees. The award was made under the company’s Director's Deferred Compensation Plan, with each unit representing one share of common stock. The RSUs, issued from the Amended and Restated 2012 Share Incentive Plan, will vest in full on May 26, 2027. Following this grant, Thomas directly holds 35,697.123 shares of Medifast common stock.
SCHLACKMAN SCOTT reported acquisition or exercise transactions in this Form 4 filing.
Medifast Inc. director Scott Schlackman received an award of 11,680 restricted stock units as part of his annual director fees. Each unit represents one share of common stock granted under the company’s share incentive plan and is scheduled to vest in full on May 26, 2027. Following this grant, Schlackman directly holds 42,228.707 shares of common stock.
Geary Elizabeth A. reported acquisition or exercise transactions in this Form 4 filing.
Medifast Inc. director Elizabeth A. Geary received a grant of 11,680 restricted stock units of common stock as part of her annual director fees under the company’s Director's Deferred Compensation Plan. The award was made at a grant price of $0.00 per share.
Each unit represents one share of Medifast common stock and will vest in full on May 26, 2027, subject to the plan terms. Following this grant, Geary’s reported direct holdings total 31,225 shares of Medifast common stock, reflecting routine, compensation-related equity issuance rather than an open-market purchase.
Xian Ming reported acquisition or exercise transactions in this Form 4 filing.
Medifast Inc. director Xian Ming received an annual grant of 11,680 cash-settled restricted stock units under the 2012 Share Incentive Plan. These units will vest in full on May 26, 2027, and each represents a right to receive the cash value of one share of common stock at vesting.
After this grant, Ming’s reported derivative holdings tied to common stock total 43,822.918 units. This is a compensation award, not an open-market stock purchase or sale.
MEDIFAST INC filed an initial insider ownership report for board member Jeffrey Matthew Rose. This Form 3 identifies Rose as a director of the company but does not list any stock transactions or current share holdings. It is a routine disclosure establishing his status as an insider for future reporting.
MEDIFAST INC director Kiai Parsa filed an initial Form 3 reporting indirect ownership of 657,590 shares of Common Stock held by Steamboat Capital investment entities. The filing states he may be deemed to have a pecuniary interest in these shares but disclaims beneficial ownership beyond that interest.
Medifast, Inc. reported stockholder approval of an amendment to its Amended and Restated 2012 Share Incentive Plan, adding authorization for 250,000 additional shares of common stock for equity awards. The amended plan became effective upon approval at the 2026 annual meeting.
The Board appointed Nicholas Johnson as Chief Executive Officer, succeeding Dan Chard, who transitions to non-executive Chairman. Johnson’s package includes a $600,000 annual base salary, a target annual bonus equal to 100% of base salary, and a long-term incentive target equal to 250% of base salary, a 69% increase versus his prior compensation as President.
Stockholders also re-elected all director nominees, ratified RSM US LLP as independent auditor for the 2026 fiscal year, approved executive compensation on an advisory basis, and approved the amended share incentive plan.
MEDIFAST, INC. joint Schedule 13G filing reports that Citadel entities and Kenneth Griffin may be deemed to beneficially own 715,910 shares of Common Stock, representing 6.5% of the class based on 11,031,693 Shares outstanding as of March 23, 2026.
The filing lists ownership by Citadel Securities LLC (712,864 shares), Citadel Securities Group LP and Citadel Securities GP LLC (each 715,910 shares), and states shared voting and dispositive power rather than sole control. The joint filing is signed May 15, 2026.
Charles Schwab Investment Management Inc. filed an amended Schedule 13G reporting beneficial ownership of 631,539 shares of Medifast Inc. Common Stock, representing 5.74% of the class as reported 03/31/2026. The amendment is signed by Omar Aguilar, Chief Executive Officer, on 05/13/2026.